{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T05:34:28Z","timestamp":1776922468359,"version":"3.51.2"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.seizure.2021.08.001","type":"journal-article","created":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T11:36:06Z","timestamp":1628249766000},"page":"2-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["Safety and tolerability of the novel 2019 coronavirus disease (COVID-19) vaccines among people with epilepsy (PwE): A cross-sectional study"],"prefix":"10.1016","volume":"92","author":[{"given":"Fathi","family":"Massoud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samar Farouk","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Medhat","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.J.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasem","family":"Al\u2013Hashel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maher","family":"Arabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.seizure.2021.08.001_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105924","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges","volume":"55","author":"Lai","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.seizure.2021.08.001_bib0002","unstructured":"WHO. COVID-19 Pandemic 2020, 11 mARCH [Available from: https:\/\/www.who.int\/director-general\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid- 19\u201411-march-2020."},{"key":"10.1016\/j.seizure.2021.08.001_bib0003","doi-asserted-by":"crossref","unstructured":"Gostin LO, Salmon DA, Larson HJJJ. Mandating COVID-19 vaccines. 2021;325(6):532-3.","DOI":"10.1001\/jama.2020.26553"},{"key":"10.1016\/j.seizure.2021.08.001_bib0004","doi-asserted-by":"crossref","unstructured":"Andre FE, Booy R, Bock HL, Clemens J, Datta SK, John TJ, et\u00a0al. Vaccination greatly reduces disease, disability, death and inequity worldwide. 2008;86:140-6.","DOI":"10.2471\/BLT.07.040089"},{"key":"10.1016\/j.seizure.2021.08.001_bib0005","doi-asserted-by":"crossref","unstructured":"Vergara RJD, Sarmiento PJD, Lagman JDNJJoph. Building public trust: a response to COVID-19 vaccine hesitancy predicament. 2021.","DOI":"10.1093\/pubmed\/fdaa282"},{"key":"10.1016\/j.seizure.2021.08.001_bib0006","doi-asserted-by":"crossref","unstructured":"Puteikis K, Mameni\u0161kien\u0117 RJIjoer, health p. Factors Associated with COVID-19 Vaccine Hesitancy among People with Epilepsy in Lithuania. 2021;18(8):4374.","DOI":"10.3390\/ijerph18084374"},{"issue":"3","key":"10.1016\/j.seizure.2021.08.001_bib0007","first-page":"165","article-title":"Assessment of precipitating factors of breakthrough seizures in epileptic patients","volume":"52","author":"Al-Kattan","year":"2015","journal-title":"Psychiatry, Neurosurg"},{"issue":"1","key":"10.1016\/j.seizure.2021.08.001_bib0008","first-page":"56","article-title":"Precipitating factor of seizure in epilepsy: experience in a tertiary care hospital","volume":"23","author":"Chowdhury","year":"2014","journal-title":"Mymensingh Med J"},{"key":"10.1016\/j.seizure.2021.08.001_bib0009","unstructured":"tracker C-v. Vaccine tracker 2021, June 11 [Available from: https:\/\/covid19.trackvaccines.org\/country\/kuwait\/."},{"key":"10.1016\/j.seizure.2021.08.001_bib0010","unstructured":"kKuwait M. Kuwait COVID-19 Vaccine 2021 [Available from: https:\/\/ourworldindata.org\/covid-vaccinations?country=OWID_WRL."},{"key":"10.1016\/j.seizure.2021.08.001_bib0011","doi-asserted-by":"crossref","unstructured":"Kim JH, Marks F, Clemens JDJNm. Looking beyond COVID-19 vaccine phase 3 trials. 2021;27(2):205-11.","DOI":"10.1038\/s41591-021-01230-y"},{"key":"10.1016\/j.seizure.2021.08.001_bib0012","doi-asserted-by":"crossref","unstructured":"Pruna D, Balestri P, Zamponi N, Grosso S, Gobbi G, Romeo A, et\u00a0al. Epilepsy and vaccinations: Italian guidelines. 2013;54:13-22.","DOI":"10.1111\/epi.12306"},{"key":"10.1016\/j.seizure.2021.08.001_bib0013","doi-asserted-by":"crossref","unstructured":"Sarkis RA, Jehi L, Bingaman W, Najm IMJE. Seizure worsening and its predictors after epilepsy surgery. 2012;53(10):1731-8.","DOI":"10.1111\/j.1528-1167.2012.03642.x"},{"issue":"34","key":"10.1016\/j.seizure.2021.08.001_bib0014","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1016\/j.vaccine.2015.04.036","article-title":"Vaccine hesitancy: Definition, scope and determinants","volume":"33","author":"MacDonald","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.seizure.2021.08.001_bib0015","unstructured":"Food U, Food DAJ, Drug administration UDoH, Services H. Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. 2007."},{"key":"10.1016\/j.seizure.2021.08.001_bib0016","unstructured":"Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et\u00a0al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial. 2020;396(10249):467-78."},{"key":"10.1016\/j.seizure.2021.08.001_bib0017","doi-asserted-by":"crossref","unstructured":"Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et\u00a0al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. 2021.","DOI":"10.1016\/S1473-3099(21)00224-3"},{"key":"10.1016\/j.seizure.2021.08.001_bib0018","doi-asserted-by":"crossref","unstructured":"Riad A, Pokorn\u00e1 A, Attia S, Klugarov\u00e1 J, Ko\u0161\u010d\u00edk M, Klugar MJJoCM. Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic. 2021;10(7):1428.","DOI":"10.3390\/jcm10071428"},{"issue":"10267","key":"10.1016\/j.seizure.2021.08.001_bib0019","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2021","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.seizure.2021.08.001_bib0020","doi-asserted-by":"crossref","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et\u00a0al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. 2020;383(27):2603-15.","DOI":"10.1056\/NEJMoa2034577"},{"key":"10.1016\/j.seizure.2021.08.001_bib0021","doi-asserted-by":"crossref","unstructured":"Barlow WE, Davis RL, Glasser JW, Rhodes PH, Thompson RS, Mullooly JP, et\u00a0al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. 2001;345(9):656-61.","DOI":"10.1056\/NEJMoa003077"},{"key":"10.1016\/j.seizure.2021.08.001_bib0022","doi-asserted-by":"crossref","unstructured":"Arnheim-Dahlstr\u00f6m L, H\u00e4llgren J, Weibull CE, Spar\u00e9n PJB. Risk of presentation to hospital with epileptic seizures after vaccination with monovalent AS03 adjuvanted pandemic A\/H1N1 2009 influenza vaccine (Pandemrix): self controlled case series study. 2012;345.","DOI":"10.1136\/bmj.e7594"},{"key":"10.1016\/j.seizure.2021.08.001_bib0023","doi-asserted-by":"crossref","unstructured":"Huang W-T, Gargiullo PM, Broder KR, Weintraub ES, Iskander JK, Klein NP, et\u00a0al. Lack of association between acellular pertussis vaccine and seizures in early childhood. 2010;126(2):263-9.","DOI":"10.1542\/peds.2009-1496"},{"key":"10.1016\/j.seizure.2021.08.001_bib0024","doi-asserted-by":"crossref","unstructured":"Shorvon S, Berg AJE. Pertussis vaccination and epilepsy\u2014an erratic history, new research and the mismatch between science and social policy. 2008;49(2):219-25.","DOI":"10.1111\/j.1528-1167.2007.01478.x"},{"key":"10.1016\/j.seizure.2021.08.001_bib0025","doi-asserted-by":"crossref","unstructured":"Gold M, Goodwin H, Botham S, Burgess M, Nash M, Kempe AJAodic. Re-vaccination of 421 children with a past history of an adverse vaccine reaction in a special immunisation service. 2000;83(2):128-31.","DOI":"10.1136\/adc.83.2.128"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131121002697?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131121002697?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:58:22Z","timestamp":1761011902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131121002697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":25,"alternative-id":["S1059131121002697"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2021.08.001","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and tolerability of the novel 2019 coronavirus disease (COVID-19) vaccines among people with epilepsy (PwE): A cross-sectional study","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2021.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}